James R Bidwell
Examiner (ID: 16151, Phone: (571)272-6910 , Office: P/3651 )
Most Active Art Unit | 3651 |
Art Unit(s) | 3651, 3101, 3615, 3107, 2899 |
Total Applications | 4628 |
Issued Applications | 4079 |
Pending Applications | 225 |
Abandoned Applications | 317 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18986498
[patent_doc_number] => 20240058467
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/349337
[patent_app_country] => US
[patent_app_date] => 2023-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 128025
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349337
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/349337 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | Jul 9, 2023 | Pending |
Array
(
[id] => 18523024
[patent_doc_number] => 20230233678
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => DENDRITIC CELL TUMOR VACCINE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/169174
[patent_app_country] => US
[patent_app_date] => 2023-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21751
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169174
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/169174 | DENDRITIC CELL TUMOR VACCINE AND USES THEREOF | Feb 13, 2023 | Pending |
Array
(
[id] => 18529998
[patent_doc_number] => 20230235066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => GLYCOME FACTORS DRIVING MELANOMA PROGRESSION
[patent_app_type] => utility
[patent_app_number] => 18/101285
[patent_app_country] => US
[patent_app_date] => 2023-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17753
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18101285
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/101285 | Glycome factors driving melanoma progression | Jan 24, 2023 | Issued |
Array
(
[id] => 18829704
[patent_doc_number] => 20230398228
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/062996
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58681
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062996
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062996 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Dec 6, 2022 | Pending |
Array
(
[id] => 18467085
[patent_doc_number] => 20230201366
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => ANTI-PSMA CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/056080
[patent_app_country] => US
[patent_app_date] => 2022-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14674
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056080
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/056080 | ANTI-PSMA CONJUGATES | Nov 15, 2022 | Pending |
Array
(
[id] => 18707663
[patent_doc_number] => 20230330242
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => IMMUNOCONJUGATES AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/936346
[patent_app_country] => US
[patent_app_date] => 2022-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936346
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/936346 | Immunoconjugates and methods | Sep 27, 2022 | Issued |
Array
(
[id] => 18278416
[patent_doc_number] => 20230093888
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
[patent_app_type] => utility
[patent_app_number] => 17/823494
[patent_app_country] => US
[patent_app_date] => 2022-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37355
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823494
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/823494 | Compositions and methods for delivery of nucleic acids to cells | Aug 29, 2022 | Issued |
Array
(
[id] => 18165461
[patent_doc_number] => 20230032060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
[patent_app_type] => utility
[patent_app_number] => 17/823492
[patent_app_country] => US
[patent_app_date] => 2022-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37311
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823492
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/823492 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | Aug 29, 2022 | Pending |
Array
(
[id] => 18324913
[patent_doc_number] => 20230123041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => IMMUNOCONJUGATES AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/812869
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38266
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812869
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/812869 | IMMUNOCONJUGATES AND METHODS | Jul 14, 2022 | Pending |
Array
(
[id] => 17944426
[patent_doc_number] => 20220331443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/851340
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 195
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851340
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/851340 | IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF | Jun 27, 2022 | Pending |
Array
(
[id] => 18196519
[patent_doc_number] => 20230050038
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => PDGF MUTANTS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/836684
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8794
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836684
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836684 | PDGF MUTANTS AND METHODS OF USE THEREOF | Jun 8, 2022 | Pending |
Array
(
[id] => 18308720
[patent_doc_number] => 20230112620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA
[patent_app_type] => utility
[patent_app_number] => 17/831085
[patent_app_country] => US
[patent_app_date] => 2022-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37147
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831085
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/831085 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | Jun 1, 2022 | Abandoned |
Array
(
[id] => 18245981
[patent_doc_number] => 11602544
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-14
[patent_title] => Compositions and methods for treating EGFR positive cancers
[patent_app_type] => utility
[patent_app_number] => 17/663758
[patent_app_country] => US
[patent_app_date] => 2022-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 40
[patent_no_of_words] => 62446
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17663758
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/663758 | Compositions and methods for treating EGFR positive cancers | May 16, 2022 | Issued |
Array
(
[id] => 17830135
[patent_doc_number] => 20220267439
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => Methods for Manipulating Phagocytosis Mediated by CD47
[patent_app_type] => utility
[patent_app_number] => 17/736896
[patent_app_country] => US
[patent_app_date] => 2022-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736896
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/736896 | Methods for Manipulating Phagocytosis Mediated by CD47 | May 3, 2022 | Abandoned |
Array
(
[id] => 19058971
[patent_doc_number] => 11938164
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Exosome-based cancer assays
[patent_app_type] => utility
[patent_app_number] => 17/714295
[patent_app_country] => US
[patent_app_date] => 2022-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 40
[patent_no_of_words] => 58598
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714295
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/714295 | Exosome-based cancer assays | Apr 5, 2022 | Issued |
Array
(
[id] => 17945765
[patent_doc_number] => 20220332782
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => Combined Artificial Cell Death/Reporter System Polypeptide for Chimeric Antigen Receptor Cell and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/657803
[patent_app_country] => US
[patent_app_date] => 2022-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28617
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657803
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/657803 | Combined Artificial Cell Death/Reporter System Polypeptide for Chimeric Antigen Receptor Cell and Uses Thereof | Apr 3, 2022 | Pending |
Array
(
[id] => 17533692
[patent_doc_number] => 20220112301
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
[patent_app_type] => utility
[patent_app_number] => 17/560006
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33212
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560006
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/560006 | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma | Dec 21, 2021 | Issued |
Array
(
[id] => 18085561
[patent_doc_number] => 11535679
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-27
[patent_title] => Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
[patent_app_type] => utility
[patent_app_number] => 17/558404
[patent_app_country] => US
[patent_app_date] => 2021-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 6
[patent_no_of_words] => 30348
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 234
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17558404
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/558404 | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | Dec 20, 2021 | Issued |
Array
(
[id] => 18869857
[patent_doc_number] => 11857637
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => Anti-CD25 antibody-maytansine conjugates and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/519183
[patent_app_country] => US
[patent_app_date] => 2021-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 14
[patent_no_of_words] => 35282
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 355
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/519183 | Anti-CD25 antibody-maytansine conjugates and methods of use thereof | Nov 3, 2021 | Issued |
Array
(
[id] => 18230728
[patent_doc_number] => 20230069722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/356497
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71844
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -48
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | Jun 22, 2021 | Pending |